Roche receives EU committee backing for Gazyva in lupus treatment
In short
European Union committee backing represents a critical advancement for the company's treatment candidate in the autoimmune space. The recommendation supports extending the drug's therapeutic use specifically to include patients diagnosed with lupus. A formal decision from the European Commission typically follows such panel opinions to finalize authorization.
Key points
- European regulatory advisors have formally backed the therapy for patients suffering from…: European regulatory advisors have formally backed the therapy for patients suffering from lupus.
- The company has successfully achieved a crucial milestone toward broadening its drug's th…: The company has successfully achieved a crucial milestone toward broadening its drug's therapeutic reach.
- The recommendation establishes the necessary groundwork for an official approval decision…: The recommendation establishes the necessary groundwork for an official approval decision across member countries.